ImageneBio Inc. (IMA:NASDAQ) closed at $4.00 on October 19, 2026, down 0.25% on the day. The stock trades 56.0% below its 52-week high of $9.10 and 2.6% above its 52-week low of $3.90. Over the past year, it lost 46.4%. ImageneBio Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -4.94% | -19.52% | -29.49% | -32.67% | -46.42% |
In 252 trading sessions since October 16, 2025, IMA closed higher on 104 days (41%). Its best day was April 13, 2026 (+23.42%) and its worst was May 8, 2026 (-10.49%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.
Find more stocks like IMA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.